Image Map

woman on squat barby: David Tolson

This is a series devoted to exploring the use of cognition enhancing drugs and nutrients. Discussion will range from the scientific to the philosophical and everywhere in between. This first article serves as a brief introduction to the original nootropic, piracetam. Further articles will discuss other nootropic substances, while also exploring many of the issues brought up in this article in greater depth. Part I covers the history, uses, and “practical” information concerning piracetam, while part II will discuss piracetam’s mechanism of action.
History

Piracetam (also referred to as UCB-6215, 2-oxo-pyrrolidone, or 2-oxo-1-pyrrolidine acetamide; pronounced pur-AHS-uh-tam) was first synthesized in 1964 and submitted to clinical investigations in 1965 [1]. It was first reported to inhibit central nystagmus in the rabbit, and this was followed by investigations on its use in the treatment of motion sickness, vertigo, and epilepsy in children [1-3]. Between 1968 and 1972, piracetam research skyrocketed following spinal cord fixation experiments [3-4]. During this period, it was discovered that piracetam protected against amnesia caused by both hypoxia and electroshock, enhanced acquisition of passive avoidance in rats, and normalized the EEG in animals subjected to hypoxia. By 1972, 700 papers had been published concerning piracetam [3-4]. In 1971, the year that piracetam first reached clinical practice (in France), C.E. Guirgea coined the term “nootropic” after Greek noos (mind) and tropos (turn towards) to describe the activity of piracetam and related compounds [4-6]. According to Guirgea, a nootropic should meet certain criteria. It must:

1) Enhance learning and memory
2) Enhance resistance of learned behavior to disruptive conditions
3) Protect the brain from physical and/or chemical injuries
4) “Increase the efficacy of the tonic cortical/subcortical control mechanisms”
5) Lack sedative, stimulant, and other such properties and has very few side effects and low toxicity [4].

However, since this initial definition was made, the term “nootropic” has in many instances become much more broad. Some sources refer to nootropics as only substances that improve memory in the absence of a cognitive deficit [7], any drug that is useful in the treatment of dementia [8], drugs that overcome natural or induced cognitive impairments [9], or a cognition enhancing drug that “lead[s] to a physiological activation of adaption,” in opposition to psychostimulants and analeptics [10]. In many cases, the term seems to be used to describe only piracetam and chemically related compounds.

After the discovery of piracetam, over 1600 structurally related molecules (all containing the pyrrolidine structure) were synthesized, over 300 of which have been studied pre-clinically [6, 11]. About a dozen of these substances have been licensed or are in advanced stages of clinical development in various areas of the world (primarily Asia). This list includes aniracetam, fasoracetam, levetiracetam, nebracetam, nefiracetam, oxiracetam, and pramiracetam [6]. Rolziracetam is also of interest. All of these compounds possess nootropic activity and none exhibit CNS toxicity [6].

Animal Studies

Piracetam’s effects on learning and memory have been studied using a multitude of experimental paradigms. Cognitive enhancement from piracetam has been demonstrated in rats, mice, guinea pigs, rabbits, cats, marmosets, dogs, goldfish, and cockroaches [4, 6, 12-14]. Piracetam has inhibited the amnesic effects induced by anticholinergics (such as scopolamine), cycloheximide, hexachlorophene, barbiturates, baclofen, diazepam, alcohol, cerebral injuries, hypercapnia (excessive CO2), hypoxia, electroshock, ischemia, malnourishment, environmental impoverishment, and aging [4, 6, 8-9, 15-17]. Animal models in which piracetam has been beneficial include passive avoidance, active and conditional avoidance, object recognition, matching-to-sample, choice reaction, delayed comparison tasks, delayed alternation tasks, match-to-position tasks, social learning, win-stay water-escape tasks, the Y maze, the eight-arm radial maze, the Morris water maze, the elevated plus-maze, and tests of complex motor function (note that many of these overlap) [6-7, 11, 18-21]. Collectively, these results imply facilitation of both acquisition and retention along with both long term memory (LTM) and short term memory (STM), to name but a few. Piracetam also has effects in animal models of depression, anxiety, stress, and exploratory behavior, but we will discuss this in more depth in later articles.

While a large amount of the research on piracetam is carried out in aged or otherwise impaired animals, there has still been a considerable amount of study on healthy, normal ones. Indeed, many of these models (such as scopolamine-induced amnesia) may have little application for healthy humans, as they are primarily aimed towards screening for anti-dementia drugs. Piracetam does improve memory in normal animals, although this effect tends to be much less pronounced [8, 15, 17, 22-24]. Whether or not this carries over into healthy humans will be discussed in further detail below.

Although all of the research discussed above has been positive, there is some research indicating a piracetam-induced impairment of memory, specifically piracetam impaired reversal learning and extinction in a three-choice test [20]. In this paradigm, rats first undergo a training phase in which they are taught to pick the correct of three boxes for a reward. Piracetam facilitates the speed at which this ability is acquired and decreases the number of errors. However, in the reversal-learning test, a different one of the three boxes is rewarded, and the speed at which the animal learns to go to that new box rather than the previous one is measured. Piracetam inhibits this process of “relearning.” During extinction, none of the boxes is rewarded. In this test, piracetam slows the rate at which animals realize that the previously rewarded box is now a waste of their time.

Although extinction is differentiated from forgetting (as amnesic agents impair, rather than facilitate extinction), piracetam’s effect may not indicate an impairment of learning in this case. Rather, the test results may indicate that piracetam is strengthening consolidation of the original memory. However, affirming this hypothesis would be very difficult. If we are to take the effects on reversal learning at face value, it would appear that piracetam may impair acquisition of a new skill if that new skill is in opposition to a previously learned skill. As mentioned above, this could only be due to increased consolidation of the original memory, rather than an impairment of acquisition, as multiple tests have demonstrated that piracetam facilitates the speed and strength of acquisition. This leads one to speculate whether any cognitive enhancer could cause improvement on the reversal learning and extinction tests. It is also noteworthy that an earlier study found piracetam to facilitate acquisition but not interfere with extinction [25]. For further discussion on this topic, see Christoffersen et al. [20].

Human Studies

Piracetam is an approved drug in many parts of the world, for conditions including alcohol withdrawal, alcoholism, head injuries, learning disorders, vertigo, dyslexia, post-traumatic vertigo and coma, sickle-cell anemia, epilepsy, Raynaud’s disease, and Parkinson’s disease [6]. Recent research has focused on the use of piracetam in cortical myoclonus (severe muscle spasms) [26]. It is also commonly used to treat brain disturbances and intellectual disorders caused by tranquilizers, neuroleptics, depressants, barbiturates, electroconvulsive therapy, and agents that impair brain circulation; mild cognitive impairment (MCI); Alzheimer’s disease; intrauterine hypoxia in prematurely born infants; ischemic stroke; and aphasia [5-6, 20, 27]. A multitude of other possible benefits have also been identified, such as treatment of schizophrenia, depression, congestive heart failure, myocardial infarction, arrhythmia, hypertension, fetal alcohol syndrome, sudden deafness, neuropathic pain, viral neuroinfections, breath holding spells, burn wounds, hypoxia associated with altitude and hazardous jobs, motion sickness, bronchitis, gastric ulcers, cancer, and cerebral palsy [3, 5, 28-39]. There are also data on stress, anxiety, and depression, but like the animal research this will be discussed in a later article.

As is the case with most nootropics, the data on memory improvement in healthy humans are limited. In 1976, a double-blind study was conducted to determine if piracetam could improve verbal learning in normal volunteers. It was found that piracetam did not significantly improve verbal learning at the one-week point, but did so at the two-week point [40]. Some studies have also been conducted in normal individuals subjected to hypoxia (oxygen deprivation). In a double-blind study with crossover design, piracetam’s effect on the concentration of 12 subjects under hypoxic conditions was determined. Piracetam did not affect the speed of the concentration test, but significantly lowered the number of errors, having a more pronounced effect during longer periods of oxygen deprivation [31]. Other studies have found that piracetam protects against the detrimental effects of high altitudes [41]. Some research has also been done on aging individuals without significant cognitive impairment. In a single-blind study, piracetam was associated with improvement on a number of clinical scales [42]. In a study on driving capacity of elderly motorists, piracetam improved scores on a driving test from 77.08% to 84.16% compared to 79.86% to 80.07% with placebo (the tests were spaced six weeks apart) [43]. Finally, piracetam has reportedly improved memory function in hypertensive patients “exposed to psychoemotional stress at work” [32].

When it comes to MCI and other age-related mental illnesses, there is a much greater research base. Instead of looking at individual studies, we can draw conclusions from meta-analyses and reviews. A meta-analysis conducted last year following the Cochrane Collaboration methodology found that the existing evidence suggests that piracetam has a favorable effect in many types of age-related cognitive impairments [44]. Other reviews agree with these findings, especially in the cases of mild to moderate dementia [2-3]. Present data indicates that piracetam is as effective as cholinesterase inhibitors in the treatment of dementia [2, 45].

All in all, it appears that the effect on humans is similar to the effect on animals, with modest memory improvements seen in healthy individuals and more pronounced improvements in individuals in which memory is compromised in a variety of ways, including chemical, physical, and mental stress.

Dosage and Pharmacokinetics

Side effects resulting from piracetam are very rare (equivalent to placebo values), and serious side effects are unheard of, even at doses of 24 grams daily [6, 46]. There is one exception, which is that piracetam may worsen the symptoms of Huntington’s disease [47-48]. There are also no known significant drug interactions [6]. Acutely, doses of 8 g/kg IV in rats and 10 g/kg orally in rats, dogs, and mice have been tested without achieving an LD50 [3-4], and rats have been treated with 1 g/kg orally for six months and dogs with 10 g/kg for one year without any signs of toxicity, teratogenicity, or behavioral tolerance [4]. All of this makes piracetam “one of the toxicologically safest drugs ever developed” [4].

Piracetam is highly water soluble and stable and has no known metabolites [8]. It is excreted primarily, but not solely, by the kidneys [6, 49]. It has an oral bioavailability of almost 100%, and maximum levels in the bloodstream are reached in 30-50 minutes, with a plasma half-life of about 4-5 hours [6]. In contrast, CNS levels reach the maximum amount in 4-5 hours and the CNS half-life is 7.7 hours [3, 22-23]. Piracetam does not appear to accumulate in the brain [50-51], although the literature is contradictory on this point [3]. However, chronic use seems to be more effective than acute use at enhancing memory [22, 52]. The possible reasons for this will be discussed in more detail in part II of this series.

It is important to know that the dose-response curve for piracetam, at least in the case of memory enhancement, follows an inverted U or bell shape, so higher doses are not necessarily better [5, 23, 27, 53]. In contrast, the effectiveness in treating certain ailments, such as cortical myoclonus, cerebellar ataxia, and alcohol organic mental disorder gets progressively higher with increasing dosages, with up to 60 g daily being reported [54-56]. This makes it unwise to believe that the dosages that are effective for treatment of certain conditions cross over to those for memory enhancement in healthy individuals. In rats, 300 mg/kg seems to be the most commonly used dose, in rabbits, 50-300 mg/kg is the effective range [57], and in chicks, 100 mg/kg displays nootropic activity whereas 300 mg/kg does not [23], indicating an interspecies variation in the effective dose.

The most effective dosage for healthy humans appears to be in the range of 2.4-4.8 g (equating to roughly 30-60 mg/kg in an 80 kg individual). In a study measuring Global Dimensional Complexity from an acute dose in healthy individuals, the maximal effect was seen at 2.4 g, with 9.6 g showing minimal effects and 4.8 g in between the two [27]. However, another EEG study found the most significant effect at 4.8 g as compared to 2.4 and 9.6 g [53]. It is worthy of note that the first study mentioned used young subjects, while the second one used older individuals. The dosage used successfully on healthy individuals was 4.8 g [40-41], but this was not compared with a different amount.

Drug Combinations

There are also a number of substances thought to enhance the activity of piracetam. The most well known is choline. The combination of piracetam and choline is reported to be synergistic when used to treat dementia [19]; a study in mice indicates that 50 mg/kg piracetam along with 50 mg/kg choline IP was superior to up to 1000 mg/kg of piracetam alone or up to 200 mg/kg of choline alone [58]. Another study in rats found 100 mg/kg of both piracetam and choline to be superior to 200 mg/kg of either substance on its own [59]. Finally, researchers found that when normally ineffective doses of piracetam and citicholine (a nootropic form of choline) were combined, retention was enhanced at both the 24-hour and the 7-day point [60]. Other substances that piracetam has been reported to synergize with include vitamin B6 (for hypoxia), phosphatidylserine (for Alzheimer’s treatment), and hydergine [3-4, 61]. James South, MA, also hypothesizes that other B vitamins, NADH, lipoic acid, coenzyme Q10 or idebenone, and magnesium may all enhance the activity of piracetam [4].

Piracetam has also been studied in conjunction with stimulants such as caffeine, amphetamine, and methamphetamine. In electroshock-induced amnesia, caffeine can differentially synergize with piracetam to produce increased memory enhancement or disrupt acquisition depending on the experimental conditions, whereas no interaction was noted between piracetam and amphetamine [62]. However, piracetam and methamphetamine had a synergistic effect in the same active avoidance paradigm [63]. Piracetam has also been noted to decrease the amnesic effect of diazepam without interfering with the anxiolytic activity [64].

Conclusion

In conclusion, piracetam has shown to be beneficial in a variety of ways without any toxicity. The optimal dosage is 2.4-4.8 g daily, but it would be best to stay on the lower end if one is taking synergistic supplements. It is possible that use of stimulants such as caffeine will interfere with the activity of piracetam. Part II will discuss the enigmatic mechanism of action of this memory-enhancing drug.

For questions or comments regarding this article, email [email protected].

References

1. Frostl W, Maitre L. The families of cognition enhancers. Pharmacopsychiatry. 1989 Oct;22 Suppl 2:54-100.

2. Mondadori C. Nootropics: preclinical results in the light of clinical effects; comparison with tacrine. Crit Rev Neurobiol. 1996;10(3-4):357-70.

3. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev. 1994 May;19(2):180-222.

4. South, James. Piracetam: The Original Nootropic. http://www.piracetam.info.

5. Vaglenova J, Vesselinov Petkov V. Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance? Eur Neuropsychopharmacol. 2001 Feb;11(1):33-40.

6. Shorvon S. Pyrrolidone derivatives. Lancet. 2001 Dec 1;358(9296):1885-92

7. Kumar V, Singh PN, Muruganandam AV, Bhattacharya SK. Effect of Indian Hypericum perforatum Linn on animal models of cognitive dysfunction. J Ethnopharmacol. 2000 Sep;72(1-2):119-28.

8. Muller WE, Eckert GP, Eckert A. Piracetam: novelty in a unique mode of action. Pharmacopsychiatry. 1999 Mar;32 Suppl 1:2-9.

9. Galeotti N, Ghelardini C, Bartolini A. Pharmacol Biochem Behav. Piracetam and aniracetam antagonism of centrally active drug-induced antinociception. 1996 Apr;53(4):943-50.

10. Herrmann WM, Coper H. Are nootropics a separate class of drugs? A differentiation in various models. Methods Find Exp Clin Pharmacol. 1987 Mar;9(3):173-82. [abstract]

11. Gualtieri F, Manetti D, Romanelli MN, Ghelardini C. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des. 2002;8(2):125-38

12. Inozemtsev AN, Tselkova NV, Bernui LKh, Zhuzhikov DP, Tushmalova NA. [The effect of piracetam on the behavior of Nauphoeta cinerea cockroaches in an open field] [Article in Russian]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1998 Mar-Apr;48(2):260-6. [abstract]

13. Moyanova S, Nikolov R, Dimov S. Effect of piracetam on the electrocorticogram after traumatic brain oedema in cats. Methods Find Exp Clin Pharmacol. 1985 Dec;7(12):623-6. [abstract]

14. Nikolova M, Tsikalova R, Nikolov R, Taskov M. Simultaneous investigation of the cerebral circulation and cortical bioelectrical activity in dogs under the influence of piracetam. Methods Find Exp Clin Pharmacol. 1979 Jun;1(2):97-104. [abstract]

15. Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berl). 1990;101(2):147-59.

16. Pan JC, Zhang SS. [Antagonism of piracetam on the amnestic effect of diazepam in mice] [Article in Chinese]. Yao Xue Xue Bao. 1996;31(2):91-4. [abstract]

17. Jaiswal AK, Upadhyay SN, Bhattacharya SK. Effect of piracetam, a nootropic agent, on discrimination learning deficits induced by parental undernutrition and environmental impoverishment in young rats. Indian J Exp Biol. 1989 Mar;27(3):269-73. [abstract]

18. Ghelardini C, Galeotti N, Bartolini A. Pro-cognitive activity induced in the rat by low doses of R-(+)-hyoscyamine. Fitoterapia. 2000 Aug;71 Suppl 1:S124-30.

19. Lee SC, Moon YS, You KH. Effects of red ginseng saponins and nootropic drugs on impaired acquisition of ethanol-treated rats in passive avoidance performance. J Ethnopharmacol. 2000 Jan;69(1):1-8.

20. Christoffersen GR, Kemp A, Orlygsdottir G. Piracetam inhibits Pavlovian extinction and reversal learning in a spatial task for rats. Neuropharmacology. 1998 Jun;37(6):815-25.

21. Janicke B, Wrobel D. Changes in motor activity with age and the effects of pharmacologic treatment. Exp Gerontol. 1984;19(5):321-8. [abstract]

22. Christoffersen GR, von Linstow Roloff E, Nielsen KS. Effects of piracetam on the performance of rats in a delayed match-to-position task. Prog Neuropsychopharmacol Biol Psychiatry. 1998 Jan;22(1):211-28.

23. Loscertales M, Rose SP, Daisley JN, Sandi C. Piracetam facilitates long-term memory for a passive avoidance task in chicks through a mechanism that requires a brain corticosteroid action. Eur J Neurosci. 1998 Jul;10(7):2238-43.

24. Salimov R, Salimova N, Shvets L, Shvets N. Effect of chronic piracetam on age-related changes of cross-maze exploration in mice. Pharmacol Biochem Behav. 1995 Nov;52(3):637-40.

25. Sara SJ, David-Remacle M, Weyers M, Giurgea C. Piracetam facilitates retrieval but does not impair extinction of bar-pressing in rats. Psychopharmacology (Berl). 1979 Mar 14;61(1):71-5. [abstract]

26. Wischer S, Paulus W, Sommer M, Tergau F. Piracetam affects facilitatory I-wave interaction in the human motor cortex. Clin Neurophysiol. 2001 Feb;112(2):275-9

27. Kondakor I, Michel CM, Wackermann J, Koenig T, Tanaka H, Peuvot J, Lehmann D. Single-dose piracetam effects on global complexity measures of human spontaneous multichannel EEG. Int J Psychophysiol. 1999 Oct;34(1):81-7.

28. Garcia Callejo FJ, Velert Vila MM, Morant Ventura A, Orts Alborch MH, Marco Algarra J, Blay Galaud L. [Pathophysiological rationale for the use of piracetam in sudden deafness] [Article in Spanish]. Acta Otorrinolaringol Esp. 2000 May;51(4):319-26. [abstract]

29. Donma MM. Clinical efficacy of piracetam in treatment of breath-holding spells. Pediatr Neurol. 1998 Jan;18(1):41-5. [abstract]

30. Danilova EI, Grafova VN, Reshetniak VK. [The action of piracetam and its complex with sodium oxybutyrate in the neuropathic pain syndrome] [Article in Russian]. Eksp Klin Farmakol. 1996 Jul-Aug;59(4):8-10. [abstract]

31. Nagornev SN, Sytnik SI, Bobrovnitskii IP, Cherniakov IN, Shishov AA. [Pharmacological correction of lipid peroxidation during hypoxia and possibility to enhance human resistance to high altitude by using preparations of the metabolic type of action] [Article in Russian]. Vestn Ross Akad Med Nauk. 1996;(7):53-60. [abstract]

32. Dasaeva LA. [Effects of piracetam on occupationally significant functions of patients with arterial hypertension working under conditions of psychoemotional stress] [Article in Russian]. Med Tr Prom Ekol. 1995;(10):26-8. [abstract]

33. Tsorin IB, Kazanova GV, Chichkanov GG. [The long-term use of antihypoxants in myocardial infarct in rats: their effect on the hemodynamics and contractile function of the heart] [Article in Russian]. Eksp Klin Farmakol. 1993 May-Jun;56(3):25-7. [abstract]

34. Samvelian VM, Malakian MG, Badzhinian SA. [The antiarrhythmic action of piracetam] [Article in Russian]. Farmakol Toksikol. 1990 Nov-Dec;53(6):22-3. [abstract]

35. Nikitin AV, Chesnokova IV, Sysoeva LI. [The efficacy of piracetam in treating patients with chronic bronchitis and concomitant atherosclerosis] [Article in Russian]. Vrach Delo. 1990 Nov;(11):17-8. [abstract]

36. Goel RK, Chakravarty M, Abbas WR, Singh KP, Bhattacharya SK. Effect of piracetam, a nootropic agent, on experimental gastric ulcers in rat. Indian J Exp Biol. 1990 Apr;28(4):337-40. [abstract]

37. von Metzler A, Nitsch C. Carcinogenesis and the central nervous system. Cancer Detect Prev. 1986;9(3-4):259-77. [abstract]

38. Niss AI, Umanskii KG, Maksutova EL, Rudometov IuP. [Efficacy of piracetam treatment of acute viral neuroinfections] [Article in Russian]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1985;85(2):189-95. [abstract]

39. Maritz NG, Muller FO, Pompe van Meerdervoort HF. Piracetam in the management of spasticity in cerebral palsy. S Afr Med J. 1978 Jun 3;53(22):889-91. [abstract]

40. Dimond SJ, Brouwers EM. Increase in the power of human memory in normal man through the use of drugs. Psychopharmacology (Berl). 1976 Sep 29;49(3):307-9. [abstract]

41. Demay F, Bande J. The effect of piracetam on volunteers in a low-pressure tank. J Int Med Res. 1980;8(1):90-4. [abstract]

42. Gallai V, Mazzotta G, Del Gatto F, Montesi S, Mazzetti A, Dominici P, Della Monica A. A clinical and neurophysiological trial on nootropic drugs in patients with mental decline. Acta Neurol (Napoli). 1991 Feb;13(1):1-12. [abstract]

43. Schmidt U, Brendemuhl D, Engels K, Schenk N, Ludemann E. Piracetam in elderly motorists. Pharmacopsychiatry. 1991 Jul;24(4):121-6. [abstract]

44. Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord. 2002;13(4):217-24. [abstract]

45. Tsolaki M, Pantazi T, Kazis A. Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer’s disease: a retrospective, longitudinal study. J Int Med Res. 2001 Jan-Feb;29(1):28-36. [abstract]

46. De Reuck J, Van Vleymen B. The clinical safety of high-dose piracetam–its use in the treatment of acute stroke. Pharmacopsychiatry. 1999 Mar;32 Suppl 1:33-7.

47. Mateo D, Gimenez-Roldan S. [The effect of piracetam on involuntary movements in Huntington’s disease. A double-blind, placebo-controlled study] [Article in Spanish]. Neurologia. 1996 Jan;11(1):16-9. [abstract]

48. Destee A, Petit H, Warot P. Effect of piracetam in Huntington’s chorea. Eur Neurol. 1984;23(2):89-91. [abstract]

49. Rameis H, Hitzenberger G, Kutscher R, Manigley C. Pharmacokinetics of piracetam: a study on the bioavailability with special regard to renal and non-renal elimination. Int J Clin Pharmacol Ther. 1994 Sep;32(9):458-65. [abstract]

50. Scheuer K, Rostock A, Bartsch R, Muller WE. Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. Pharmacopsychiatry. 1999 Mar;32 Suppl 1:10-6.

51. Tacconi MT, Wurtman RJ. Physiological disposition of oral piracetam in Sprague-Dawley rats. J Pharm Pharmacol. 1984 Oct;36(10):659-62. [abstract]

52. Krapivin SV, Sopyev ZhA. [The effect of preparations with nootropic action when used long-term on the brain bioelectrical activity in rats] [Article in Russian]. Eksp Klin Farmakol. 1993 Jan-Feb;56(1):6-9. [abstract]

53. Michel CM, Lehmann D. Single doses of piracetam affect 42-channel event-related potential microstate maps in a cognitive paradigm. Neuropsychobiology. 1993;28(4):212-21. [abstract]

54. Genton P, Guerrini R, Remy C. Piracetam in the treatment of cortical myoclonus. Pharmacopsychiatry. 1999 Mar;32 Suppl 1:49-53.

55. Vural M, Ozekmekci S, Apaydin H, Altinel A. High-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy. Mov Disord. 2003 Apr;18(4):457-9. [abstract]

56. Barnas C, Miller C, Ehrmann H, Schett P, Gunther V, Fleischhacker WW. High versus low-dose piracetam in alcohol organic mental disorder: a placebo controlled study. Psychopharmacology (Berl). 1990;100(3):361-5. [abstract]

57. Voronina TA, Molodavkin GM, Borlikova GG, Ostrovskaia RU, Tushmalova NA, Naznamov GG. [The nootropic and anxiolytic properties of different doses of piracetam] [Article in Russian]. Eksp Klin Farmakol. 2000 Mar-Apr;63(2):9-11. [abstract]

58. Platel A, Jalfre M, Pawelec C, Roux S, Porsolt RD. Habituation of exploratory activity in mice: effects of combinations of piracetam and choline on memory processes. Pharmacol Biochem Behav. 1984 Aug;21(2):209-12. [abstract]

59. Bartus RT, Dean RL 3rd, Sherman KA, Friedman E, Beer B. Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiol Aging. 1981 Summer;2(2):105-11. [abstract]

60. Mosharrof AH, Petkov VD. Effects of citicholine and of the combination citicholine + piracetam on the memory (experiments on mice). Acta Physiol Pharmacol Bulg. 1990;16(1):25-31. [abstract]

61. Costall B, Barnes JM, Hamon M, Muller WE, Briley M. Biochemical models for cognition enhancers. Pharmacopsychiatry. 1990 Feb;23 Suppl 2:85-8; discussion 89.

62. Petkov VD, Konstantinova E, Petkov VV, Lazarova M, Petkova B. Modulation of the effects on learning and memory of nootropic drugs and central stimulants when applied together. Acta Physiol Pharmacol Bulg. 1991;17(4):17-26. [abstract]

63. Arch Int Pharmacodyn Ther. 1985 Dec;278(2):229-35. Interaction between nootropic drugs and methamphetamine on avoidance acquisition but not on locomotor activity in mice. Sansone M, Ammassari-Teule M, Oliverio A. [abstract]

64. Lenegre A, Chermat R, Avril I, Steru L, Porsolt RD. Specificity of piracetam’s anti-amnesic activity in three models of amnesia in the mouse. Pharmacol Biochem Behav. 1988 Mar;29(3):625-9. [abstract]

×